Sanofi and Denali Therapeutics collaborate to develop treatments for neurological and inflammatory diseases
Jones Day represented Sanofi in its strategic collaboration and license agreement with Denali Therapeutics for the development, manufacturing, and commercialization of many pre-clinical and clinical candidates for treatment of certain neurological and systemic inflammatory diseases, including those known to target RIPK1, such as MS, Alzheimer's Disease and ALS, and rheumatoid arthritis. Sanofi pays $125 million to Denali upfront with future development and commercial milestone payments that could exceed $1 billion. The agreement also contains payments through cost-profit sharing in the U.S. and China and royalties in other countries. Jones Day also provided antitrust support for HSR clearance for the transaction.